Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income. The company anticipates range-bound margins and moderating revenue growth in FY27, driven by specialty launches and R&D spending. Domestic formulations remain robust, while US segment recovery is expected to be gradual.
Macro headwinds are behind us; largecaps poised to outperform: Prashant Jain
India’s equity markets are poised for a positive turn as economic challenges recede, according to Prashant Jain. He highlights strong domestic fundamentals, improving external balances,
July 2, 2026